The new approval will allow BGG to market its AstaZine line throughout Europe. This important achievement builds on two previous successful petitions for AstaZine with the US FDA: the first at a dose that does not exceed 12mg of Astaxanthin per day, and the second at a dose that does not exceed 24mg of Astaxanthin per day for a period of 30 days.
Following the substantial equivalence opinion released by the Food Safety Authority of Ireland, AstaZine will be placed on the EU market as an ingredient in food supplements at the current levels of usage.
Commenting on the news, Christian Artaria, CEO of BGG Europe and CMO of BGG group, said: “We are extremely pleased to receive this approval that allows us to market AstaZine throughout all EU countries. We are also extremely happy with our regulatory submission track record in EU and US with our fourth successful notification on AstaZine.""This is not only a sign of the quality of BGG products, but also a sign of the excellent service that we provide to our customers including our regulatory support,” he added.
AstaZine in powder form is the first and only organic (NOP) astaxanthin product on the market.
BGG will be displaying from 29 November-1 December 2016 at Hi Europe & Ni in Frankfurt at booth #L71.